Concurrent Docetaxel Plus Cisplatin or Cisplatin Alone With IMRT in High Risk Nasopharyngeal Carcinoma
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
The investigators aim to evaluate the efficiency and toxicities of concurrent docetaxel and
cisplatin with intensity-modulated radiotherapy in high risk locoregionally advanced
nasopharyngeal carcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Sun Yat-sen University
Collaborators:
Affiliated Cancer Hospital & Institute of Guangzhou Medical University Affiliated Tumor Hospital of Guangzhou Medical University The First Affiliated Hospital of Guangdong Pharmaceutical University The First Affiliated Hospital of Guangzhou Medical University